Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don't Look Positive

Visen Pharmaceuticals IPO: Unfavorable Trends

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

VISEN Pharmaceuticals / Equity Capital Markets

<ul>
<li>Visen Pharmaceuticals is looking at raising up to USD 100m to list in Hong Kong.</li>
<li>In an apparently downsized deal, the company is trying to sell at a blue sky valuation.</li>
<li>We disagree with its valuation and noted that tones have turned bearish in its offering documents.</li>
</ul>


Visen Pharmaceuticals is looking at raising up to USD 100m to list in Hong Kong.
In an apparently downsized deal, the company is trying to sell at a blue sky valuation.
We disagree with its valuation and noted that tones have turned bearish in its offering documents.


Anhui Anke Biotechnology (Group) (300009 CH)

Pharmaceuticals (维升药业) IPO: Valuation and Book Building